Access to investigational medicines for terminally ill through expanded access programs

Bottom Line: A new study identified investigational medicines made available through expanded access programs for patients with life-threatening illnesses prior to approval from the U.S. Food and Drug Administration to assess the timing and duration of investigational drug availability.

Authors: Joseph S. Ross, M.D., M.H.S., of Yale University School of Medicine, New Haven, Connecticut, and coauthors

  <p><strong>To Learn More:</strong> The full study is available on the For The Media website.</p>    <p>(doi:10.1001/jamanetworkopen.2018.0283)</p>      <p>Editor's Note: The article contains conflict of interest and funding support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.</p>   <p>###</p>  <strong>Want to embed a link to this study in your story?: </strong>Links will be live at the embargo time    <p><strong>About JAMA Network Open:</strong> JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. Every Friday, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.  </p>                               <p><strong>Media Contact</strong></p>    <p>Ziba Kashef  <br />[email protected]